Abstract 5795: The discovery of BLU-020: A potent and selective degrader of CDK2 for the treatment of CCNE1 aberrant cancers
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Phil Ramsden, Dean Zhang, Maria Iliou, Suhasini Parimi, Jeff Keats, Maxine Chen, Lakshmi Muthuswamy, Guangyan Du, Fereidoon Daryaee, Ben Barlock, James Baker, Sue Spong, Ken Kearney, Gramoz Kondakci, Deborah G. Conrady, Stella Li, Xavier Fradera, Yinghui Dai, Tina Tran, Tom Dineen, Chiara Conti
Institution: Blueprint Medicines (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7148689352
Cites:
Cited by:
Related to: